The efficacy of thiotropium bromide (Spiriva) in the treatment of patients with chronic obstructive pulmonary disease of varying severity: results of the Russian trial

Abstract


Aim. To evaluate the efficacy and safety of Spiriva (thiotropium bromide 18 μg for inhalation via a HandiHaler device) in patients with chronic obstructive pulmonary disease (COPD) of all severities in routine clinical practice in Russia.
Subjects and methods. The study enrolled 407 patients (68 women and 339 men) with COPD who used thiotropium bromide (Spiriva) for 8 weeks. Most (72.3%) of the patients were aged 50-70 years; active smokers were 64.9%; ex-smokers were 27%; smoking duration averaged 38.6 pack-years; Severe, moderate, very severe, and mild COPD was observed in 38.6, 37.3, 18.4, and 5.7%, respectively. By the start of the trial, 305 (74.5%) had received concomitant therapy.
Results. After 8-week thiotropium bromide therapy, there was a significant increase in bronchial patency, as suggested by considerable increments in the postbronchial indices: forced expiratory volume in one second (FEV1) by an average of 290 ml (20.4%) of the baseline level during treatment and forced vital capacity (FVC) by 310 ml (12.1%). By the end of the trial, the mean increase in inspiratory capacity (IC) by 180 ml (8.07%) of the baseline value was indicative of decreased lung hyperinflation in the treated patients. The significant increment in mean FEV1, FVC, and IC was observed in patients with any severity of COPD.
Conclusion. The RUSSE study has indicated that there may be very good results in patients with COPD of any severity and a steady-state positive effect just after 8-week thiotropium bromide treatment. This treatment improves bronchial patency and diminishes lung hyperinflation, thus improving the patients' health status and exercise endurance.

About the authors

Igor' Emil'evich Stepanyan

Email: drstepanyan@mail.ru

Natal'ya Georgievna Khmel'kova

Brigita Bellin-Atarak

I E Stepanyan

N G Khmelkova

B Belin-Atarac

References

  1. Casabury R., Mahler D., Jones P. et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
  2. Vincken W., van Noord J. A., Greefhorst A. P. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
  3. Donohue J., van Noord J. A., Bateman E. D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
  4. Niewoehner D. E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator, a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
  5. Johansson G., Lindberg A., Romberg K. et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim. Care. Respir. J. 2008; 17: 169-175.
  6. Decramer M., Celli B., Tashkin D. P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: UPLIFT trial. COPD 2004; 1: 303-312.
  7. Tashkin D. P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
  8. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
  9. Хроническая обструктивная болезнь легких: Практ. руководство для врачей. М.; 2004.
  10. American Thoracic Society. Standartisation of spirometry, 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107- 1136.

Statistics

Views

Abstract - 52

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies